Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a 7-Day antibiotic course be as effective as 14 days for COPD attacks?

NCT ID NCT07708337

Disease control Sponsor: Capital Development Authority (CDA) Hospital Islamabad Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This trial investigates whether a 7-day course of antibiotics works as well as the standard 14-day course for adults hospitalized with a sudden worsening of COPD. The study involves over 500 participants and measures clinical success at 30 days, including symptom improvement and avoidance of additional antibiotics or readmission. The goal is to see if shorter treatment can reduce antibiotic use, side effects, and the risk of antibiotic resistance without compromising patient outcomes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a 7-day course of systemic antibiotics compared to the usual 14-day course
What this could lead to
If successful, a shorter antibiotic course could become standard for COPD flare-ups, reducing side effects and helping fight antibiotic resistance.
What could go wrong
This is a single trial in one country, and shorter treatment might not work as well for all patients, potentially leading to more treatment failures.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 502 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Feb 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 90 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 18 years or older * Physician-diagnosed COPD, confirmed by post-bronchodilator spirometry (FEV1/FVC \< 0.70) where available, or by documented prior spirometry consistent with COPD * Current acute exacerbation of COPD requiring antibiotic therapy in the judgment of the treating physician, with at least two cardinal symptoms (increased dyspnoea, sputum volume, or sputum purulence) * Able and willing to provide written informed consent and to comply with study procedures and follow-up Exclusion Criteria: * Documented infection requiring a defined prolonged antibiotic course (e.g. pneumonia with complications, bronchiectasis exacerbation, lung abscess, empyema) * Need for immediate intensive care admission or invasive mechanical ventilation at presentation * Severe immunosuppression (e.g. neutropenia, active malignancy on chemotherapy, organ transplantation, advanced HIV) * Suspected or confirmed pulmonary tuberculosis or another respiratory infection requiring a different antimicrobial approach * Pregnancy or breastfeeding * Prior enrolment in this trial or current participation in another interventional AECOPD trial.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute exacerbation of COPD are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease COPD, severe early onset

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute exacerbation of COPD COPD

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CDA Hospital Islamabad

    Islamabad, Pakistan, 44000, Pakistan

More trials for these conditions

Other studies related to the condition(s) this trial covers.